<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019626</url>
  </required_header>
  <id_info>
    <org_study_id>CA22747</org_study_id>
    <nct_id>NCT04019626</nct_id>
  </id_info>
  <brief_title>A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes</brief_title>
  <official_title>An Open-label, Parallel Study to Assess Tobacco-related Biomarkers of Exposure, Biomarkers of Potential Harm, and Nicotine Uptake During a 56-day Switch to Myblu E-cigarettes in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fontem Ventures BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fontem Ventures BV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess changes in exposure to selected harmful and&#xD;
      potentially harmful substances related to tobacco/nicotine use when adult smokers switch from&#xD;
      their usual brand of combustible cigarettes to the myblu e-cigarette, for up to 56 days. This&#xD;
      study is designed as an open-label, partially-randomized, parallel-arm, multi-site study in&#xD;
      healthy adult smokers.&#xD;
&#xD;
      Some subjects will be selected to take part in additional procedures as part of a&#xD;
      pharmacokinetics (PK) sub-study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are randomized to either continue smoking conventional cigarettes, or switch to use&#xD;
      the myblu e-cigarette. Within the &quot;myblu&quot; arm, subjects were assigned to one of four variants&#xD;
      of the myblu e-cigarette, having different flavors and nicotine strengths. Initial product&#xD;
      assignment for each subject was based on preference as a method to enhance compliance. To&#xD;
      further improve compliance through Day 56, subjects may have been allowed to choose to switch&#xD;
      to another variant of the myblu e-cigarette, or to continue using the same e-liquid selected&#xD;
      initially.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Carboxyhemoglobin in Blood</measure>
    <time_frame>Baseline and 56 days</time_frame>
    <description>Change from baseline in the % saturation of carboxyhemoglobin (COHb) in whole blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Urine in 24 Hours</measure>
    <time_frame>Baseline and 56 days</time_frame>
    <description>Change from baseline in the amount of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL - a biomarker of exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) excreted in urine in 24-hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of 3-hydroxypropylmercapturic Acid in Urine in 24 Hours</measure>
    <time_frame>Baseline and 56 days</time_frame>
    <description>Change from baseline in the amount of 3-hydroxypropylmercapturic acid (3-HPMA - a biomarker of exposure to acrolein) excreted in urine in 24-hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of S-phenyl Mercapturic Acid in Urine in 24 Hours</measure>
    <time_frame>Baseline and 56 days</time_frame>
    <description>Change from baseline in the amount of s-phenyl mercapturic acid (S-PMA - a biomarker of exposure to benzene) excreted in urine in 24-hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of Nicotine Equivalents in Urine in 24 Hours</measure>
    <time_frame>Baseline and 56 days</time_frame>
    <description>The change from baseline in the amount of nicotine equivalents excreted in urine in 24-hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of White Blood Cells</measure>
    <time_frame>Baseline and 56 days</time_frame>
    <description>The change from baseline in the level of white blood cells, which is a biomarker of potential harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Measure: Nicotine Withdrawal Symptoms Total Score</measure>
    <time_frame>56 days</time_frame>
    <description>Nicotine withdrawal symptoms are measured using the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R) questionnaire. The DSM-5 and craving items from the MTWS-R have been included. The subjects rate themselves on the questionnaire, which includes symptoms such as angry, irritable, frustrated, depressed mood, restless, insomnia. Each question is rated from 0 (none) to 4 (severe). Total scores may range from 0 to a maximum of 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Nicotine Concentration in Blood</measure>
    <time_frame>5 minutes prior, and at 3, 5, 7, 10, 12, 15, 20, 30, 60, 120 and 180 minutes post dose</time_frame>
    <description>The maximum nicotine concentration in blood (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Continue-smoking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subject's usual brand of combustible cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Tobacco 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Tobacco flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Tobacco 4.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Tobacco flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Honeymoon 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Honeymoon flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu Honeymoon 4.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>myblu e-cigarette system with Honeymoon flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JUUL 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>JUULÂ® system with Virginia Tobacco Flavor JUULpod, 5.0% nicotine. This arm is only included in the PK sub-study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continue-smoking</intervention_name>
    <description>Ad-libitum use of subjects' usual brand combustible cigarette</description>
    <arm_group_label>Continue-smoking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Tobacco 2.5%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine</description>
    <arm_group_label>myblu Tobacco 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Tobacco 4.0%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine</description>
    <arm_group_label>myblu Tobacco 4.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Honeymoon 2.5%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine</description>
    <arm_group_label>myblu Honeymoon 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu Honeymoon 4.0%</intervention_name>
    <description>Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine</description>
    <arm_group_label>myblu Honeymoon 4.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL 5%</intervention_name>
    <description>Ad-libitum use of JUUL 5% e-cigarette</description>
    <arm_group_label>JUUL 5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having smoked â¥5 manufactured combustible cigarettes per day for at least one year&#xD;
&#xD;
          -  Exhaled carbon monoxide level of &gt;10 ppm at screening&#xD;
&#xD;
          -  Tested positive for urinary cotinine (approximately 200 ng/mL) at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant illness history&#xD;
&#xD;
          -  Relevant medication use&#xD;
&#xD;
          -  Body mass index (BMI) of less than 18 kg/m2 or greater than 40 kg/m2&#xD;
&#xD;
          -  Allergy to propylene glycol or glycerin&#xD;
&#xD;
          -  Use of nicotine-containing products other than manufactured cigarettes&#xD;
&#xD;
          -  Use of prescription smoking cessation treatments&#xD;
&#xD;
          -  Smokers who draw smoke into their mouth and throat but do not inhale&#xD;
&#xD;
          -  Intent or desire to stop smoking&#xD;
&#xD;
          -  Female subjects who are pregnant, lactating, or intend to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <results_first_submitted>April 14, 2021</results_first_submitted>
  <results_first_submitted_qc>June 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04019626/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04019626/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Myblu Tobacco Flavor 2.5%</title>
          <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
        </group>
        <group group_id="P2">
          <title>Myblu Tobacco Flavor 4.0%</title>
          <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
        </group>
        <group group_id="P3">
          <title>Myblu Honeymoon 2.5%</title>
          <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
        </group>
        <group group_id="P4">
          <title>Myblu Honeymoon 4.0%</title>
          <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
        </group>
        <group group_id="P5">
          <title>Continue-smoking</title>
          <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
        </group>
        <group group_id="P6">
          <title>JUUL 5%</title>
          <description>Use of JUUL 5% nicotine e-cigarette</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population: randomized subjects in the main study with at least one documented product-use experience from Day 1. The JUUL5% arm is not included as it was used only for the PK sub-study as a secondary objective, and not the main study.</population>
      <group_list>
        <group group_id="B1">
          <title>Myblu Tobacco Flavor 2.5%</title>
          <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
        </group>
        <group group_id="B2">
          <title>Myblu Tobacco Flavor 4.0%</title>
          <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
        </group>
        <group group_id="B3">
          <title>Myblu Honeymoon 2.5%</title>
          <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
        </group>
        <group group_id="B4">
          <title>Myblu Honeymoon 4.0%</title>
          <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
        </group>
        <group group_id="B5">
          <title>Continue-smoking</title>
          <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="46"/>
            <count group_id="B5" value="44"/>
            <count group_id="B6" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="46"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="11.72"/>
                    <measurement group_id="B2" value="37.8" spread="10.47"/>
                    <measurement group_id="B3" value="40.3" spread="9.43"/>
                    <measurement group_id="B4" value="40.3" spread="9.75"/>
                    <measurement group_id="B5" value="39.7" spread="10.44"/>
                    <measurement group_id="B6" value="39.6" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="46"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="46"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="46"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="4.7"/>
                    <measurement group_id="B2" value="30.0" spread="4.9"/>
                    <measurement group_id="B3" value="28.9" spread="4.7"/>
                    <measurement group_id="B4" value="28.9" spread="5.2"/>
                    <measurement group_id="B5" value="29.9" spread="5.6"/>
                    <measurement group_id="B6" value="29.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood carboxyhemoglobin (COHb) %</title>
          <units>% saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="46"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="2.2"/>
                    <measurement group_id="B2" value="4.8" spread="1.8"/>
                    <measurement group_id="B3" value="4.8" spread="2.1"/>
                    <measurement group_id="B4" value="5.3" spread="1.9"/>
                    <measurement group_id="B5" value="5.7" spread="2.0"/>
                    <measurement group_id="B6" value="5.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) amount excreted in urine</title>
          <population>Some samples were missing</population>
          <units>ng/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="45"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411.0" spread="333.2"/>
                    <measurement group_id="B2" value="406.8" spread="328.8"/>
                    <measurement group_id="B3" value="410.4" spread="351.2"/>
                    <measurement group_id="B4" value="479.4" spread="404.2"/>
                    <measurement group_id="B5" value="513.7" spread="403.7"/>
                    <measurement group_id="B6" value="444.26" spread="346.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>3-hydroxypropylmercapturic acid (3-HPMA) amount excreted in urine</title>
          <population>Some samples were missing</population>
          <units>ug/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="45"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1592.5" spread="818.2"/>
                    <measurement group_id="B2" value="1730.3" spread="1044.2"/>
                    <measurement group_id="B3" value="1749.7" spread="780.1"/>
                    <measurement group_id="B4" value="1919.0" spread="999.8"/>
                    <measurement group_id="B5" value="2214.0" spread="1172.6"/>
                    <measurement group_id="B6" value="1841.1" spread="963.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>S-phenyl mercapturic acid (S-PMA) amount excreted in urine</title>
          <population>Some samples were missing</population>
          <units>ug/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="45"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="3.7"/>
                    <measurement group_id="B2" value="5.9" spread="4.3"/>
                    <measurement group_id="B3" value="6.5" spread="5.1"/>
                    <measurement group_id="B4" value="7.2" spread="5.2"/>
                    <measurement group_id="B5" value="8.6" spread="5.9"/>
                    <measurement group_id="B6" value="6.7" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nicotine equivalents amount excreted in urine</title>
          <population>Some samples were missing</population>
          <units>mg/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="42"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="45"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="6.8"/>
                    <measurement group_id="B2" value="14.1" spread="7.5"/>
                    <measurement group_id="B3" value="17.1" spread="13.3"/>
                    <measurement group_id="B4" value="16.2" spread="6.5"/>
                    <measurement group_id="B5" value="18.0" spread="7.3"/>
                    <measurement group_id="B6" value="15.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Level of white blood cells</title>
          <population>Some samples were missing</population>
          <units>cells*thousands/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="46"/>
                    <count group_id="B5" value="44"/>
                    <count group_id="B6" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="2.0"/>
                    <measurement group_id="B2" value="7.0" spread="2.0"/>
                    <measurement group_id="B3" value="6.8" spread="1.8"/>
                    <measurement group_id="B4" value="7.4" spread="2.0"/>
                    <measurement group_id="B5" value="7.2" spread="2.2"/>
                    <measurement group_id="B6" value="7.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Carboxyhemoglobin in Blood</title>
        <description>Change from baseline in the % saturation of carboxyhemoglobin (COHb) in whole blood</description>
        <time_frame>Baseline and 56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (cf &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different from the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Carboxyhemoglobin in Blood</title>
          <description>Change from baseline in the % saturation of carboxyhemoglobin (COHb) in whole blood</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (cf &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different from the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.6" spread="23.3"/>
                    <measurement group_id="O2" value="-62.7" spread="19.4"/>
                    <measurement group_id="O3" value="-46.4" spread="35.1"/>
                    <measurement group_id="O4" value="-62.7" spread="21.2"/>
                    <measurement group_id="O5" value="8.5" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Urine in 24 Hours</title>
        <description>Change from baseline in the amount of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL - a biomarker of exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) excreted in urine in 24-hours</description>
        <time_frame>Baseline and 56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Urine in 24 Hours</title>
          <description>Change from baseline in the amount of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL - a biomarker of exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) excreted in urine in 24-hours</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.3" spread="72.8"/>
                    <measurement group_id="O2" value="-44.7" spread="150.5"/>
                    <measurement group_id="O3" value="-62.7" spread="36.2"/>
                    <measurement group_id="O4" value="-70.7" spread="33.7"/>
                    <measurement group_id="O5" value="1.1" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of 3-hydroxypropylmercapturic Acid in Urine in 24 Hours</title>
        <description>Change from baseline in the amount of 3-hydroxypropylmercapturic acid (3-HPMA - a biomarker of exposure to acrolein) excreted in urine in 24-hours</description>
        <time_frame>Baseline and 56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of 3-hydroxypropylmercapturic Acid in Urine in 24 Hours</title>
          <description>Change from baseline in the amount of 3-hydroxypropylmercapturic acid (3-HPMA - a biomarker of exposure to acrolein) excreted in urine in 24-hours</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.0" spread="28.2"/>
                    <measurement group_id="O2" value="-55.7" spread="46.1"/>
                    <measurement group_id="O3" value="-50.5" spread="36.2"/>
                    <measurement group_id="O4" value="-53.8" spread="64.5"/>
                    <measurement group_id="O5" value="1.6" spread="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of S-phenyl Mercapturic Acid in Urine in 24 Hours</title>
        <description>Change from baseline in the amount of s-phenyl mercapturic acid (S-PMA - a biomarker of exposure to benzene) excreted in urine in 24-hours</description>
        <time_frame>Baseline and 56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of S-phenyl Mercapturic Acid in Urine in 24 Hours</title>
          <description>Change from baseline in the amount of s-phenyl mercapturic acid (S-PMA - a biomarker of exposure to benzene) excreted in urine in 24-hours</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.9" spread="32.5"/>
                    <measurement group_id="O2" value="-44.9" spread="257.5"/>
                    <measurement group_id="O3" value="-63.1" spread="79.3"/>
                    <measurement group_id="O4" value="-73.8" spread="55.7"/>
                    <measurement group_id="O5" value="-2.7" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Nicotine Equivalents in Urine in 24 Hours</title>
        <description>The change from baseline in the amount of nicotine equivalents excreted in urine in 24-hours</description>
        <time_frame>Baseline and 56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Nicotine Equivalents in Urine in 24 Hours</title>
          <description>The change from baseline in the amount of nicotine equivalents excreted in urine in 24-hours</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="74.0"/>
                    <measurement group_id="O2" value="16.6" spread="61.1"/>
                    <measurement group_id="O3" value="-13.8" spread="54.5"/>
                    <measurement group_id="O4" value="-1.3" spread="38.8"/>
                    <measurement group_id="O5" value="-7.0" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of White Blood Cells</title>
        <description>The change from baseline in the level of white blood cells, which is a biomarker of potential harm</description>
        <time_frame>Baseline and 56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Level of White Blood Cells</title>
          <description>The change from baseline in the level of white blood cells, which is a biomarker of potential harm</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="16.7"/>
                    <measurement group_id="O2" value="-4.3" spread="16.8"/>
                    <measurement group_id="O3" value="-8.7" spread="17.9"/>
                    <measurement group_id="O4" value="-8.5" spread="16.3"/>
                    <measurement group_id="O5" value="4.7" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Measure: Nicotine Withdrawal Symptoms Total Score</title>
        <description>Nicotine withdrawal symptoms are measured using the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R) questionnaire. The DSM-5 and craving items from the MTWS-R have been included. The subjects rate themselves on the questionnaire, which includes symptoms such as angry, irritable, frustrated, depressed mood, restless, insomnia. Each question is rated from 0 (none) to 4 (severe). Total scores may range from 0 to a maximum of 32.</description>
        <time_frame>56 days</time_frame>
        <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Measure: Nicotine Withdrawal Symptoms Total Score</title>
          <description>Nicotine withdrawal symptoms are measured using the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R) questionnaire. The DSM-5 and craving items from the MTWS-R have been included. The subjects rate themselves on the questionnaire, which includes symptoms such as angry, irritable, frustrated, depressed mood, restless, insomnia. Each question is rated from 0 (none) to 4 (severe). Total scores may range from 0 to a maximum of 32.</description>
          <population>Available data from the Intent-to-treat population (ITT; randomized subjects in the main study with at least one documented product-use experience from Day 1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects analysed in one arm may be different than the number of subjects who were initially assigned to this product at the study start. JUUL arm was only for PK sub-study</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="6.7"/>
                    <measurement group_id="O2" value="5.7" spread="5.5"/>
                    <measurement group_id="O3" value="7.1" spread="5.3"/>
                    <measurement group_id="O4" value="6.8" spread="5.8"/>
                    <measurement group_id="O5" value="8.1" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Nicotine Concentration in Blood</title>
        <description>The maximum nicotine concentration in blood (Cmax)</description>
        <time_frame>5 minutes prior, and at 3, 5, 7, 10, 12, 15, 20, 30, 60, 120 and 180 minutes post dose</time_frame>
        <population>Sub-group of participants who participated in the PK sub-study, on Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>Myblu Tobacco Flavor 2.5%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
          </group>
          <group group_id="O2">
            <title>Myblu Tobacco Flavor 4.0%</title>
            <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
          </group>
          <group group_id="O3">
            <title>Myblu Honeymoon 2.5%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
          </group>
          <group group_id="O4">
            <title>Myblu Honeymoon 4.0%</title>
            <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
          </group>
          <group group_id="O5">
            <title>Continue-smoking</title>
            <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
          </group>
          <group group_id="O6">
            <title>JUULÂ® 5.0%</title>
            <description>Use of JUULÂ® system with Virginia Tobacco Flavor JUULPod, 5.0% nicotine</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Nicotine Concentration in Blood</title>
          <description>The maximum nicotine concentration in blood (Cmax)</description>
          <population>Sub-group of participants who participated in the PK sub-study, on Day 1</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="196.3"/>
                    <measurement group_id="O2" value="7.3" spread="118.6"/>
                    <measurement group_id="O3" value="4.3" spread="191.3"/>
                    <measurement group_id="O4" value="8.9" spread="159.8"/>
                    <measurement group_id="O5" value="13.5" spread="62.5"/>
                    <measurement group_id="O6" value="6.9" spread="160.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 days (58 study days plus 14 follow-up days) for all arms except JUUL. 15 day for JUUL arm.</time_frame>
      <desc>Adverse events of the Safety Population (all subjects with at least one reported product use from Day -1) is presented. Subjects using the myblu e-cigarette were allowed to switch product variant in the course of the study (see &quot;Study Description&quot;). Therefore, the number of subjects at risk in one arm may be different than the number of subjects who were initially assigned to this product at the study start.</desc>
      <group_list>
        <group group_id="E1">
          <title>Myblu Tobacco Flavor 2.5%</title>
          <description>Use of myblu e-cigarette system with tobacco flavor 2.5% nicotine</description>
        </group>
        <group group_id="E2">
          <title>Myblu Tobacco Flavor 4.0%</title>
          <description>Use of myblu e-cigarette system with tobacco flavor 4.0% nicotine</description>
        </group>
        <group group_id="E3">
          <title>Myblu Honeymoon 2.5%</title>
          <description>Use of myblu e-cigarette system with Honeymoon flavor 2.5% nicotine</description>
        </group>
        <group group_id="E4">
          <title>Myblu Honeymoon 4.0%</title>
          <description>Use of myblu e-cigarette system with Honeymoon flavor 4.0% nicotine</description>
        </group>
        <group group_id="E5">
          <title>Continue-smoking</title>
          <description>The subject's usual brand of combustible cigarette&#xD;
Continue-smoking: Ad-libitum use of subjects' usual brand combustible cigarette</description>
        </group>
        <group group_id="E6">
          <title>JUULÂ® 5.0%</title>
          <description>Use of JUULÂ® system with Virginia Tobacco Flavor JUULPod, 5.0% nicotine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Morris</name_or_title>
      <organization>Nerudia Ltd</organization>
      <phone>+44 7508 708 917</phone>
      <email>paul.morris@nerudia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

